Loading…

Interleukin-27 Early Impacts Leishmania infantum Infection in Mice and Correlates with Active Visceral Disease in Humans

The complexity of -host interactions, one of the main leishmaniasis issues, is yet to be fully understood. We detected elevated IL-27 plasma levels in European patients with active visceral disease caused by , which returned to basal levels after successful treatment, suggesting this cytokine as a p...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2016-11, Vol.7, p.478-478
Main Authors: Pérez-Cabezas, Begoña, Cecílio, Pedro, Robalo, Ana Luisa, Silvestre, Ricardo, Carrillo, Eugenia, Moreno, Javier, San Martín, Juan V, Vasconcellos, Rita, Cordeiro-da-Silva, Anabela
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The complexity of -host interactions, one of the main leishmaniasis issues, is yet to be fully understood. We detected elevated IL-27 plasma levels in European patients with active visceral disease caused by , which returned to basal levels after successful treatment, suggesting this cytokine as a probable infection mediator. We further addressed this hypothesis recurring to two classical susceptible visceral leishmaniasis mouse models. BALB/c, but not C57BL/6 mice, showed increased IL-27 systemic levels after infection, which was associated with an upregulation of IL-27p28 expression by dendritic cells and higher parasite burdens. Neutralization of IL-27 in acutely infected BALB/c led to decreased parasite burdens and a transient increase in IFN-γ splenic T cells, while administration of IL-27 to C57BL/6 promoted a local anti-inflammatory cytokine response at the site of infection and increased parasite loads. Overall, we show that, as in humans, BALB/c IL-27 systemic levels are infection dependently upregulated and may favor parasite installation by controlling inflammation.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2016.00478